CSC
AUTL

Caldwell Sutter Capital’s Autolus Therapeutics AUTL Stock Holding History

Caldwell Sutter Capital’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$800 Hold
500
– – ﹤0.01% 869
2026
Q1 		$690 Hold
500
– – ﹤0.01% 838
2025
Q4 		$995 Hold
500
– – ﹤0.01% 809
2025
Q3 		$815 Hold
500
– – ﹤0.01% 809
2025
Q2 		$1.14K Hold
500
– – ﹤0.01% 772
2025
Q1 		$775 Hold
500
– – ﹤0.01% 810
2024
Q4 		$1.18K Buy
+500
New +$1.69K ﹤0.01% 805

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Caldwell Sutter Capital's AUTL Position: Q2 2026 in Review

Caldwell Sutter Capital held its Autolus Therapeutics (AUTL) position steady in Q2 2026 at 500 shares worth $800. The position accounts for ﹤0.01% of the portfolio, ranked #869.

Caldwell Sutter Capital first reported a position in AUTL in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.18K in Q4 2024. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Caldwell Sutter Capital held 500 shares of Autolus Therapeutics worth $800 as of Q2 2026.
  • Caldwell Sutter Capital left its Autolus Therapeutics share count unchanged in Q2 2026.
  • Autolus Therapeutics made up ﹤0.01% of Caldwell Sutter Capital's portfolio in Q2 2026, its #869 holding.
  • Caldwell Sutter Capital first reported a position in Autolus Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Caldwell Sutter Capital's Autolus Therapeutics position peaked at $1.18K in Q4 2024.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Caldwell Sutter Capital's 13F filing for Q2 2026, filed 5 Aug 2026.